For instance, conditions like systemic lupus erythematosus and Sjögren’s syndrome, where abnormal B cell proliferation and autoantibody production are core features, could see improved patient outcomes through combined BAFF and APRIL inhibition (203). The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.